Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | AHCY | P23526 | 4/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADA | P00813 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21015893 | 0.90 | HTR2C (0.41) | HTR2CHTR2BTMIGD3ADORA3ADORA2A | |
| SCHEMBL19778486 | 0.89 | HTR2C (0.41) | HTR2CHTR2BTMIGD3ADORA3AHCY | |
| SCHEMBL19777952 | 0.81 | ADORA2A (0.36) | HTR2CHTR2BTMIGD3ADORA3AHCY | |
| SCHEMBL19644740 | 0.80 | ADORA2A (0.47) | HTR2CHTR2BTMIGD3LMNANT5E | |
| SCHEMBL19778494 | 0.79 | CCNE2 (0.37) | HTR2CHTR2BTMIGD3NT5EADORA3 | |
| SCHEMBL19778108 | 0.79 | CCNE2 (0.37) | HTR2CHTR2BTMIGD3NT5EADORA3 | |
| SCHEMBL19859703 | 0.78 | ADORA2A (0.46) | LMNANT5EHIF1AADORA3AHCY | |
| SCHEMBL21015826 | 0.77 | HTR2C (0.32) | HTR2CHTR2BADORA3ADORA2AADORA2B | |
| SCHEMBL19765995 | 0.76 | HTR2C (0.44) | HTR2CHTR2BTMIGD3LMNANT5E | |
| SCHEMBL21016259 | 0.76 | P2RY1 (0.42) | HTR2CHTR2BADORA3AHCYADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | Atea Pharmaceuticals, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | Atea Pharmaceuticals, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2019-05-23 | — | — | US | disclosed |
| WO-2018013937-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | PNP, SLC29A2, NT5C2 | HTR2C 1522/4885HTR2B 2105/4885TMIGD3 4380/4885 |
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | PNP, SLC29A2, NT5C2 | HTR2C 1604/4885HTR2B 2248/4885TMIGD3 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.